

CITATION REPORT

List of articles citing

Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials

DOI: 10.1007/s00125-004-1549-6
Diabetologia, 2004, 47, 1914-23.

Source: <https://exaly.com/paper-pdf/37018880/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
147	Current World Literature. 2005 , 16, 658-690		
146	Phosphodiesterase type 5 inhibitors for erectile dysfunction. 2005 , 96, 257-80		153
145	An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy. 2005 , 96, 1323-32		78
144	The therapeutic dilemma: how to use tadalafil. 2005 , 28 Suppl 2, 74-80		36
143	The efficacy of tadalafil in clinical populations. <i>Journal of Sexual Medicine</i> , 2005 , 2, 517-31	1.1	56
142	Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial. <i>Journal of Sexual Medicine</i> , 2005 , 2, 685-98	1.1	22
141	Current literature in diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2005 , 21, 560-7	7.5	
140	Tadalafil: a clinical update. 2005 , 1, 203-214		3
139	Potency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor. 2005 , 1, 295-301		3
138	Erectile Dysfunction. 2005 , 23, 105-113		5
137	Frequently asked questions about tadalafil for treating men with erectile dysfunction. 2005 , 2, 141-157		1
136	PDE-5 inhibitors: current status and future trends. 2005 , 32, 511-25, viii		25
135	Diabetic neuropathies: diagnosis and treatment. 2006 , 41, 697-717, ix		4
134	Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study. 2006 , 85, 1496-501		86
133	Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled study. 2006 , 68, 845-51		18
132	Erectile Dysfunction in Diabetes: An Endothelial Disorder. 2006 , 165-178		1
131	. 2006 ,		21

130	Hormones, Metabolism, Aging and Men's Health. 225-288		11
129	Pathophysiology and treatment of diabetic erectile dysfunction. 2006 , 8, 675-84		88
128	Prevalence of erectile dysfunction in thyroid disorders: comparison with control subjects and with obese and diabetic patients. <i>International Journal of Impotence Research</i> , 2006 , 18, 111-4	2.3	34
127	VOICES AND CHOICES: PHYSICIAN, PATIENT, AND PARTNER PERSPECTIVES ON THE MANAGEMENT OF ERECTILE DYSFUNCTION. <i>Journal of Sexual Medicine</i> , 2006 , 3, 4-9	1.1	
126	Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: Scheduled use vs. on-demand regimen evaluation (SURE) study in 14 European countries. <i>Journal of Sexual Medicine</i> , 2006 , 3, 512-20	1.1	29
125	Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. <i>Journal of Sexual Medicine</i> , 2006 , 3, 650-661	1.1	45
124	Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate. <i>Journal of Sexual Medicine</i> , 2006 , 3, 668-675	1.1	14
123	Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2006 , 3, 883-891	1.1	56
122	Pharmacology of erectile dysfunction in man. 2006 , 111, 400-23		44
121	Erectile dysfunction and coronary atherothrombosis in diabetic patients: pathophysiology, clinical features and treatment. 2006 , 4, 173-80		14
120	Erectile dysfunction and diabetes mellitus: mechanistic considerations from studies in experimental models. 2007 , 3, 149-58		27
119	Endothelial microparticles correlate with erectile dysfunction in diabetic men. <i>International Journal of Impotence Research</i> , 2007 , 19, 161-6	2.3	44
118	Efficacy and safety of tadalafil in men with erectile dysfunction following spinal cord injury. 2007 , 64, 1584-92		50
117	Metabolic risk factors, endothelial dysfunction, and erectile dysfunction in men with diabetes. 2007 , 334, 466-80		14
116	Sexual dysfunction in men and women with endocrine disorders. 2007 , 369, 597-611		220
115	Phosphodiesterase type 5 inhibitors: state of the therapeutic class. 2007 , 34, 507-15, vi		23
114	A comparison of the efficacy and tolerability of tadalafil 10 mg and 20 mg in Japanese patients with severe erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2007 , 4, 745-752	1.1	6
113	Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. 2007 , CD002187		50

112	Diabetic Neuropathy. 2007 ,		7
111	Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. <i>International Journal of Impotence Research</i> , 2007 , 19, 281-95	2.3	33
110	Diagnosis and management of erectile dysfunction in the primary care setting. 2007 , 61, 1198-208		13
109	Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors. 2007 , 61, 1547-54		20
108	Management of erectile dysfunction in diabetes: an update for 2008. 2008 , 8, 437-43		8
107	Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. 2008 , 25, 138-46		97
106	Vardenafil in men with stable statin therapy and dyslipidemia. <i>Journal of Sexual Medicine</i> , 2008 , 5, 1455-67		36
105	Phenotypic assessment of endothelial microparticles in diabetic and nondiabetic men with erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2008 , 5, 1436-42	1.1	32
104	The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. 2009 , 30, 23-32		179
103	Sexual dysfunction after simultaneous pancreas-kidney transplantation. 2008 , 40, 927-30		19
102	Psychosocial impact and effectiveness of tadalafil among treatment-naïve and previously-treated men with erectile dysfunction in Saudi Arabia and other Gulf-region countries. 2008 , 24, 1965-73		8
101	Treatment strategies for diabetic patients suffering from erectile dysfunction. 2008 , 9, 257-66		15
100	Efficacy and safety of tadalafil once daily: considerations for the practical application of a daily dosing option. 2008 , 24, 3383-92		35
99	Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. 2008 , 17, 855-64		16
98	Response to treatment with tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline. <i>International Journal of Impotence Research</i> , 2008 , 20, 554-60	2.3	3
97	Tadalafil in the treatment of lower urinary tract symptoms and erectile dysfunction. 2008 , 5, 355-365		2
96	Tadalafil in the treatment of erectile dysfunction. 2008 , 4, 1315-30		57
95	Efficacy and safety of tadalafil taken as needed for the treatment of erectile dysfunction in Asian men: results of an integrated analysis. 2009 , 11, 423-33		7

94	Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study. 2009 , 11, 629-37		1
93	The burden and extent of comorbid conditions in patients with erectile dysfunction. 2009 , 63, 1205-13		42
92	Toward a new ÆPOCH optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction. 2009 , 63, 1214-30		17
91	Five-year experience with tadalafil in the UK: an effective treatment for erectile dysfunction. 2009 , 63, 1231-6		
90	Cardiovascular Endocrinology. 2009 ,		2
89	Erectile dysfunction and diabetes mellitus. 2009 , 4, 114-122		14
88	Erectile Dysfunction and Cardiovascular Disease: Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors in Men With Both Conditions. <i>Mayo Clinic Proceedings</i> , 2009 , 84, 139-148	6.4	76
87	Treatment of erectile dysfunction in the older diabetic patient. 2010 , 6, 9-29		
86	Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medications. <i>Journal of Sexual Medicine</i> , 2010 , 7, 244-55	1.1	18
85	Considerations for diagnostic criteria for erectile dysfunction in DSM V. <i>Journal of Sexual Medicine</i> , 2010 , 7, 654-60	1.1	27
84	Nebivolol dilates human penile arteries and reverses erectile dysfunction in diabetic rats through enhancement of nitric oxide signaling. <i>Journal of Sexual Medicine</i> , 2010 , 7, 2681-97	1.1	21
83	Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebo-controlled clinical trial. <i>Journal of Sexual Medicine</i> , 2010 , 7, 2842-50	1.1	25
82	Treatment of Erectile Dysfunction. 341-354		
81	Effect of intensive glycemc therapy on erectile function in men with type 1 diabetes. 2011 , 185, 1828-34		62
80	Stopwatch-assessed duration of erection: a new measure of the efficacy of erectile dysfunction treatments. <i>International Journal of Impotence Research</i> , 2011 , 23, 9-16	2.3	5
79	Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2011 , 8, 851-64	1.1	9
78	Imbalanced low-grade inflammation and endothelial activation in patients with type 2 diabetes mellitus and erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2011 , 8, 2017-30	1.1	47
77	Erectile dysfunction and cardiovascular disease. 2011 , 123, 7-16		11

76	Glyco-metabolic profile among type 2 diabetic patients with erectile dysfunction. 2012 , 59, 611-9		9
75	Erectile dysfunction and diabetes: a review of the current evidence-based medicine and a synthesis of the main available therapies. 2012 , 38, 1-13		85
74	Survey on the perception of urogenital complications in diabetic patients. <i>World Journal of Men's Health</i> , 2012 , 30, 172-6	6.8	1
73	Tadalafil 5 mg daily treatment for type 1 diabetic premenopausal women affected by sexual genital arousal disorder. <i>Journal of Sexual Medicine</i> , 2012 , 9, 2057-65	1.1	17
72	Dysfonction Erectile. <i>Canadian Journal of Diabetes</i> , 2013 , 37, S648	2.1	
71	Stem-cell therapy for erectile dysfunction. 2013 , 13, 1585-97		34
70	Erectile dysfunction. <i>Canadian Journal of Diabetes</i> , 2013 , 37 Suppl 1, S150-2	2.1	6
69	Dysfonction Erectile. <i>Canadian Journal of Diabetes</i> , 2013 , 37, S528-S530	2.1	
68	Erectile Dysfunction. <i>Canadian Journal of Diabetes</i> , 2013 , 37, S337	2.1	
67	Assessment of the efficacy of combination therapy with folic acid and tadalafil for the management of erectile dysfunction in men with type 2 diabetes mellitus. <i>Journal of Sexual Medicine</i> , 2013 , 10, 1146-50 ^{1,1}		20
66	P144, A TGF- β antagonist peptide, synergizes with sildenafil and enhances erectile response via amelioration of cavernosal fibrosis in diabetic rats. <i>Journal of Sexual Medicine</i> , 2013 , 10, 2942-51	1.1	20
65	Efficacy and safety of once-daily tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline. <i>Journal of Sexual Medicine</i> , 2013 , 10, 844-56	1.1	5
64	Advances in Stem Cell Therapy for Erectile Dysfunction. 2014 , 2014, 1-20		5
63	Men with diabetes may require more aggressive treatment for erectile dysfunction. <i>International Journal of Impotence Research</i> , 2014 , 26, 112-5	2.3	16
62	The SIAMS-ED Trial: A National, Independent, Multicentre Study on Cardiometabolic and Hormonal Impairment of Men with Erectile Dysfunction Treated with Vardenafil. 2014 , 2014, 858715		10
61	Sexual dysfunction in diabetes. 2014 , 126, 223-32		33
60	Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway. <i>Journal of Sexual Medicine</i> , 2014 , 11, 1182-92	1.1	17
59	How to treat erectile dysfunction in men with diabetes: from pathophysiology to treatment. 2014 , 14, 545		34

58	Treatment strategies for diabetic patients suffering from erectile dysfunction: an update. 2014 , 15, 1827-36	21
57	Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents. 2015 , 51, 22-36	5
56	A comprehensive review of erectile dysfunction in men with diabetes. 2015 , 123, 141-58	47
55	Safety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitors. 2015 , 39, 635-640	
54	Prevalence and associations of erectile dysfunction in a sample of Italian males with type 2 diabetes. 2015 , 108, 329-35	23
53	Erectile dysfunction and its management in patients with diabetes mellitus. 2015 , 16, 213	19
52	Safety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitors. 2015 , 39, 635-40	9
51	Urologic Tissue Engineering and Regeneration. 2016 , 121-138	
50	Pomegranate juice causes a partial improvement through lowering oxidative stress for erectile dysfunction in streptozotocin-diabetic rat. <i>International Journal of Impotence Research</i> , 2016 , 28, 234-240 ^{2,3}	4
49	Management of erectile dysfunction in men with diabetes. 2016 , 210-219	
48	Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients. 2016 , 192, 182-9	13
47	Sexual Dysfunction. 2016 , 2154-2162.e3	1
46	Type 2 Diabetes. 2016 ,	2
45	B Cell Lymphoma-2-Modified Bone Marrow-Derived Mesenchymal Stem Cells Transplantation for the Treatment of Diabetes Mellitus-Induced Erectile Dysfunction in a Rat Model. <i>Urologia Internationalis</i> , 2017 , 98, 358-366	1.9 10
44	Longitudinal Patterns of Occurrence and Remission of Erectile Dysfunction in Men With Type 1 Diabetes. <i>Journal of Sexual Medicine</i> , 2017 , 14, 1187-1194	1.1 3
43	Skin autofluorescence (a marker for advanced glycation end products) and erectile dysfunction in diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 108-113	3.2 6
42	Sexual Dysfunction and Hypogonadism in Men With Diabetes. <i>Canadian Journal of Diabetes</i> , 2018 , 42 Suppl 1, S228-S233	2.1 11
41	Prevalence and correlates of erectile dysfunction in type 2 diabetic men: a population-based cross-sectional study in Chinese men. <i>International Journal of Impotence Research</i> , 2019 , 31, 9-14	2.3 5

40	Carotid artery intima-media thickness can predict the response of patients with erectile dysfunction to phosphodiesterase 5 inhibitors. <i>International Journal of Impotence Research</i> , 2019 , 31, 139-144	2.3	5
39	Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials. <i>World Journal of Urology</i> , 2019 , 37, 1061-1074	4	14
38	Diabetic Neuropathy and Clinical Practice. 2020 ,		
37	Effects of "metabolic memory" on erectile function in diabetic men: A retrospective case-control study. <i>Andrology</i> , 2021 , 9, 288-296	4.2	1
36	The Association Between Hemoglobin A1c Levels and Inflatable Penile Prosthesis Infection: Analysis of US Insurance Claims Data. <i>Journal of Sexual Medicine</i> , 2021 , 18, 1104-1109	1.1	
35	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 484-490	18.1	2
34	Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. <i>Diabetes/Metabolism Research and Reviews</i> , 2021 , e3494	7.5	6
33	Sexual Function in Men and Woman with Diabetes. 743-759		1
32	Genitourinary Complications. 2007 , 453-472		2
31	Evaluation and Management of Erectile Dysfunction. 2012 , 721-748.e7		6
30	Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence. <i>Clinical Interventions in Aging</i> , 2006 , 1, 439-49	4	12
29	Effect of tadalafil on erectile dysfunction in male patients with diabetes mellitus. <i>Vojnosanitetski Pregled</i> , 2007 , 64, 399-404	0.1	5
28	Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. <i>Indian Journal of Endocrinology and Metabolism</i> , 2015 , 19, 451-61	1.7	24
27	Voiding Dysfunction of Men is Associated with Metabolic Syndrome. <i>Korean Journal of Urology</i> , 2006 , 47, 257		10
26	The Influence of Treatment-emergent Adverse Reactions on Selecting Phosphodiesterase Type 5 Inhibitors. <i>Korean Journal of Urology</i> , 2006 , 47, 272		1
25	Erectile Dysfunction among Diabetic Men in Two Medical Centers in Burkina Faso: Epidemiological, Diagnosis and Therapeutic Aspects. <i>Advances in Sexual Medicine</i> , 2014 , 04, 1-5	0.2	0
24	Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor?. <i>World Journal of Men's Health</i> , 2020 , 38, 271-284	6.8	6
23	The Meaning of Metabolic Syndrome X in Patients Suffering with Benign Prostatic Hyperplasia. <i>Korean Journal of Urology</i> , 2007 , 48, 696		5

22	Diabetes mellitus and sexual dysfunction. 2007 , 53-73		
21	Diabetic Peripheral Neuropathy and Sexual Dysfunction. 2007 , 277-312		
20	Etiology and Risk Factors of Erectile Dysfunction. 2011 , 51-67		
19	References, Bibliography & Further Reading. 2012 , 287-306		
18	Medikamente zur Behandlung sexueller Funktionsstörungen. 2012 , 751-763		
17	Diabetische Folgeerkrankungen. 2014 , 239-296		
16	Erectile dysfunction as a manifestation of urogenital autonomic neuropathy in patients with type 1 diabetes: epidemiology, classification, pathophysiology, diagnosis and treatment options. <i>Diabetes Mellitus</i> , 2014 , 17, 126-132	1.6	
15	Erectile Dysfunction. 2015 , 65-116		
14	Neurovascular Evaluation in Eugonadal Men with Type 2 Diabetes Mellitus and Erectile Dysfunction: A Comparative Study between Responders and Not Responders to Phosphodiesterase 5 Inhibitors. <i>Advances in Sexual Medicine</i> , 2015 , 05, 83-88	0.2	
13	Sexual dysfunctions in obese diabetics. <i>Urologie Pro Praxi</i> , 2016 , 17, 222-225	0.1	
12	Erectile dysfunction in diabetes mellitus: A review. <i>Journal of Diabetology</i> , 2020 , 11, 1	0.8	1
11	Dysfunction of Sexual and Accessory Sex Organs. 2020 , 91-120		
10	Sexual Dysfunction and Cardiovascular Risk [Links and Solutions]. 2009 , 199-215		
9	Medikamente zur Behandlung sexueller Funktionsstörungen. 2008 , 687-699		
8	Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. <i>Mayo Clinic Proceedings</i> , 2009 , 84, 139-48	6.4	29
7	Evaluation of the Effect on Sexual Performance of a Nutraceutical Combination Containing Alpha Lipoic Acid, L. and , Compared to Placebo, Avanafil or a Combination of Nutraceutical Plus Avanafil in Males With Type 2 Diabetes Mellitus With Erectile Dysfunction.. <i>Frontiers in Endocrinology</i> , 2022 , 13, 847240	5.7	0
6	Urological disease in diabetic patient. <i>Urologie Pro Praxi</i> , 2022 , 23, 58-65	0.1	
5	Comparison of three different tadalafil regimens for erectile dysfunction treatment in patients with diabetes mellitus microvascular complications.		

- 4 Is there a relationship between mean platelet volume and response to treatment with daily tadalafil in patients with erectile dysfunction?.
- 3 STIM/Orai Inhibition as a Strategy for Alleviating Diabetic Erectile Dysfunction Through Modulation of Rat and Human Penile Tissue Contractility and in vivo Potentiation of Erectile Responses. **2022**,
- 2 Erectile Dysfunction: Causes, Diagnosis and Treatment: An Update. **2022**, 11, 6429
- 1 Erectile Dysfunction Severity: The Role of Glycometabolic Compensation and Antihyperglycemic Drugs. **2022**, 11, 7214